Europe: Food, Drugs, Healthcare, Life Sciences

Sağlık turizmi, Türk hukuku bakımından sıradan bir hizmet faaliyeti olarak kabul edilmemektedir. Sağlık turizmi şirketi nasıl kurulur, hangi lisansların alınması gerekir, ödeme ve faturalandırma yapısı nasıl oluşturulmalıdır ve hastaneler ile kliniklerle kurulacak sözleşmesel ilişkiler nasıl düzenlenmelidir gibi hususlar sıkı bir mevzuat denetimine tabidir.

Looking Ahead: The PFAS Plan sets out indicative next steps for each pillar, including detailed descriptions, territorial scope (UK‑wide or devolved), anticipated delivery timelines and responsible bodies.

Legal regulations concerning the promotion of medicines and medicinal products for human use in Türkiye aim to strike a delicate balance between protecting public health and ensuring the sector's right to pursue legitimate commercial activities.

On 11 February 2026, the Supreme Court found in favour of Dairy UK Limited ("Dairy UK"), concluding its lengthy dispute with Oatly AB ("Oatly") concerning the registration and use of Oatly's trade mark POST MILK GENERATION.

Looking Ahead: The PFAS Plan sets out indicative next steps for each pillar, including detailed descriptions, territorial scope (UK‑wide or devolved), anticipated delivery timelines and responsible bodies.

Legal regulations concerning the promotion of medicines and medicinal products for human use in Türkiye aim to strike a delicate balance between protecting public health and ensuring the sector's right to pursue legitimate commercial activities.

2025 saw a continuous and re-invigorated focus on the regulation of clinical trials in Ireland and the EU. This briefing looks at what has been happening in this space and what is set to come.

(4) Mevcut ortaklardan Eurocad S.a.r.l.'a ait 24.500.000 TL nominal değerli paylar ve Evon Yapı Proje İnşaat Mühendislik Bilgisayar Sanayi ve Ticaret AŞ'ye ait 3.500.000 TL nominal değerli paylar olmak üzere toplam 28.000.000 TL nominal değerli (C) grubu paylar halka arza konu edilecektir.

The UK Department of Health and Social Care (DHSC) has proposed to set the repayment percentage on sales of branded "newer" prescription-only medicines to the NHS at 16.5% for 2026...